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Abstract The tumor promoter phorbol 12-myristic 13-acetate 
inhibits the growth of human endothelial cells and induces the 
formation of capillary-like, tubular structures. We report the 
novel growth regulatory function of the immediate-early gene, 
edg-3, which is identical to the I~Bcx/MAD-3 gene. We employed 
phosphothioatc oligonucleotides (PTO) directed against the 
translation initiation site of It.Box to inhibit its expression. The 
antisense IgBcc PTO-treated cells exhibited an exaggerated 
growth response to fibroblast growth factor-1 (FGF-1). In 
contrast, IL-l-induced growth arrest response was not modu- 
lated. These data suggest hat the early response gene Ir.Bcc is an 
endogenous regulator of endothelial cell growth in vitro. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The vascular endothelium is a monolayer of cells that are 
quiescent under normal physiological conditions and carry 
out a diverse array of functions uch as the control of vascular 
tone [1], regulation of hemostasis [2], hemopoietic cell extra- 
vasation [3] and immune reactions [4]. Endothelial cell migra- 
tion, proliferation and differentiation are part of the angio- 
genic program that occurs in normal wound healing processes 
as well as in pathological states uch as tumor angiogenesis [5] 
and rheumatoid arthritis [6]. Endothelial cells grown in vitro 
are widely used as a model system for angiogenesis since al- 
most all of the steps involved in angiogenesis can be recapitu- 
lated under defined conditions [7]. Furthermore, regulators of 
angiogenesis, namely the fibroblast growth factors [8] and 
vascular endothelial cell growth factor [9] as proliferative 
modulators and interleukin-I (IL-I~), tumor necrosis factor 
(TNFcq, transforming rowth factor-]3 (TGF-[3) and the tu- 
mor promoter phorbol myristic acetate (PMA) as non-prolif- 
erative modulators of angiogenesis were discovered based on 
the in vitro properties of endothelial cells [10]. The cytokines 
and PMA rapidly inhibit the FGF-l- induced mitogenesis of 
endothelial cells and promote a phenotypic hange into a 
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elongated, fibroblast-like shape [11]. Prolonged treatment of 
endothelial cells grown on type-I collagen matrix with PMA 
results in the formation of capillary-like structures containing 
lumens and anastomoses [12]. This has been defined as the 
phenotypic differentiation of endothelial cells in vitro 
[10,12]. It is, however a reversible process because proteolytic 
degradation of the capillary-like, tubular structures and expo- 
sure to FGF-1 results in the reversion into a cobblestone- 
shaped, highly proliferative phenotype [13]. 
Molecular mechanisms involved in the processes of angio- 
genesis have been the subject of intensive investigation. It has 
been recognized that proteolytic modifications of the extracel- 
lular matrix are involved in the phenotypic differentiation [13]. 
In addition, the plasminogen activator activity in endothelial 
cells was induced by angiogenic preparations and the active 
principle was shown to be FGF-2 [14]. Furthermore, collagen- 
ase inhibitors blocked the phenotypic differentiation of endo- 
thelial cells into capillary-like tubules [15]. More recently, 
Montesano and colleagues have proposed that the protease 
and protease inhibitor gene expression by the endothelial cells 
is modulated by extracellular cytokines and that this balance 
may influence the phenotype of endothelial cell differentiation 
[16]. That extracellular matrix modification is important in 
endothelial cell differentiation is illustrated by several studies 
which demonstrated the differential gene regulation of colla- 
gen type I [17], the proteoglycan decorin [18], and the se- 
creted, extracellular protein SPARC [19] in differentiating en- 
dothelial cells. Indeed, rapid formation of endothelial cell 
networks that resemble tubules is achieved by plating the cells 
onto Matrigel, an extracellular matrix secreted by EHS sarco- 
ma cells which is enriched in laminin and several growth fac- 
tors and cytokines [20]. 
Early signal transduction and transcriptional events in- 
duced in differentiating endothelial cells are not well under- 
stood. The FGF family of polypeptides are thought o trans- 
duce the mitogenic signal via the tyrosine phosphorylation of
intracellular substrates [8]. The tumor promoter PMA, how- 
ever, is a potent inducer of the protein kinase C family of 
isoenzymes, which induce the serine and threonine phospho- 
rylation of cellular substrates [21]. We have focused our at- 
tention on the PMA-inducible immediate-early (IE) genes in 
human umbilical vein endothelial cells (HUVEC). In growth 
factor induction of mitogenesis in fibroblasts, the IE genes 
encode critical, regulatory proteins that are necessary for the 
cell-cycle traverse [22]. We and others have characterized IE
genes induced in endothelial cells in response to PMA [23], 
TNFe~ [24] and IL-lc~ [25]. We reported the cloning and char- 
acterization of an abundant PMA-inducible IE gene termed 
edg-I that encoded a novel G-protein-coupled receptor [26]. 
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Dixit et al. have reported the cloning of several IE genes 
induced in response to TNFc¢, including c-jun, adhesion mol- 
ecules of the selection family, a novel Zinc finger protein 
implicated in apoptosis [27] and the eck l igand B61 [28]. Re- 
cently, an IL- l - inducible IE gene encoding an amyloid-like 
protein was isolated from HUVEC [25]. In this report, we 
describe the identification of the I~B~ protein, an inhibitor 
of the NF~cB transcription factor as an IE gene product in- 
duced during the early phases of PMA- induced differentiation 
of HUVEC.  
2. Materials and methods 
2.1. Cell culture 
HUVEC were grown on fibronectin-coated dishes in medium-199 
containing 10% fetal bovine serum and 150 I.tg/ml of crude endothelial 
cell growth factor and 5 units/ml of heparin [13]. Cells were subcul- 
tured at he ratio of 1:5 and used between the passages of 3 and 12. 
At confluence, cells were maintained in medium without growth factor 
and heparin for 2 days to achieve quiescence. For growth assays, cells 
were grown in medium containing purified recombinant human FGF- 
1 and heparin and cell numbers were determined in a Coulter counter. 
The following 18mer phosphothioate oligonucleotides against I~Bct 
were synthesized and used: sense=5'-ATG TTC CAG GCG GCC 
GAG-3'; antisense=5'-CTC GGC CGC CTG GAA CAT-3'. After 
synthesis, the PTOs were washed in ethanol and dissolved in sterile 
water, heated at 95°C for 5 min and frozen in aliquots. The PTOs at 
indicated concentrations were added directly to cell culture medium 
every other day. 
2.2. RNA preparation and Northern blot analysis 
Total RNA was purified by the guanidinium isothiocyanate proce- 
dure [30]. RNA was electrophoresed on a 1% agarose gel containing 
2.2 M formaldehyde and Northern blot analysis was conducted using 
the buffer system described by Church and Gilbert [30]. Hybridiza- 
tions and washes were done at 65 ° C in 20% formamide. 
2.3. PCR-ASH cloning and sequencing procedures 
Cloning of PMA/CHX-induced cDNAs from HUVEC were done 
by PCR-ASH procedures as described previously [23]. The inducibility 
of the cDNA cloned were confirmed by Northern blot analysis. Se- 
quence analysis of the deletion subclones of the edg-3 cDNA were 
conducted using the automated DNA sequencer. Sequence homology 
searches were conducted against he Genbank and EMBL databases 
using the BLAST algorithm [31]. 
2.4. In vitro translation 
Transcripts for lrB were prepared using the T7 RNA polymerase 
transcription system (Promega Biotec). Capped mRNAs were trans- 
lated in [35S]-methionine supplemented rabbit reticulocyte lysates, sep- 
arated on a 10% SDS-PAGE and autoradiographed. In some experi- 
ments, 1 ktg each of either sense or antisense PTOs were added to the 
translation mixes. 
2.5. Metabolic labelling and immunoprecipitation 
Confluent HUVEC were treated with the sense and antisense InB~t 
PTO for 2 days. Cells were then metabolically abelled with 100 laCi/ 
35 ml of [ S]-methionine/cysteine labelling mix (New England Nuclear) 
Fig. 1. A: Quiescent HUVEC were treated with either 10 ng/ml 
FGF-1 containing 5 units/ml heparin or 20 ng/ml PMA or 10 units/ 
ml TNFct for indicated periods of time and Northern blot analysis 
was conducted using the edg-3 cDNA probe. The ethidium bro- 
mide-stained gel (rRNA) is shown to indicate the relative equiva- 
lence of RNA load. Data indicate a representative experiment which 
was repeated twice. B: Quiescent HUVEC were treated with 1 ng/ 
ml IL-lct for indicated periods of time and Northern blot analysis 
was conducted with the edg-3 eDNA probe. The ethidium bromide- 
stained gel (rRNA) is shown to indicate the relative equivalence of 
RNA load. Data indicate a representative experiment which was re- 
peated twice. 
for 4 h. Some cultures received 1 ng/ml of IL-lct during the labelling 
period. Cells were then lysed with ice cold phosphate buffered saline 
(pH 7.4) containing 0.5% Triton X-100, 10/aM of pyrrolidine dithio- 
carbamate, 10 ~tg/ml of chymosin, 10 ~tg/ml of aprotinin and 1 mM 
PMSF. Cell lysates were cleared by centrifugation, pre-cleared with 
protein-A Sepharose and immunoprecipitated with the polyelonal 
antibody raised against he recombinant human InBct protein. Immu- 
noprecipitates were resolved on a 12% SDS-PAGE, incubated in a 
fluorographic solution and autoradiographed. 
3. Results 
3.1. Characterization of  the edg-3 cDNA 
In order to clone low-abundance IE transcripts that are 
induced during the differentiation of HUVEC,  we utilized 
the PCR-ASH procedure [23] and isolated several eDNA 
probes from PMA and cycloheximide-treated (4 h) mRNA 
population. One such clone, initially termed edg-3, hybridized 
to a PMA-inducible transcript of 1.8 kb. In quiescent cells the 
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edg-3 mRNA is expressed at very low levels; however, upon 
treatment with PMA for 2 h, elevated steady-state l vels of 
transcript were observed followed by a decline at 24 h (data 
not shown) [34]. Cycloheximide alone induced the edg-3 
mRNA and 'super-induced' the kinetics of induction (data 
not shown). These data indicated that edg-3 is a PMA-induc- 
ible IE gene in HUVEC.  Both TNFc~ and IL-let induced the 
edg-3 mRNA (Fig. 1). While FGF-1 induced the steady-state 
mRNA level of edg-3 in a transient manner, the kinetics of 
induction was different (Fig. 1). 
The structure of the edg-3 cDNA was determined by DNA 
sequence analysis of the 900 bp cDNA fragment. Sequence 
analysis followed by database homology search indicated 
that edg-3 is identical to the human monocyte adherence-in- 
duced IE gene MAD-3/I~Bc~ [28]. Thus, the edg-3 gene is 
hereinafter referred to as the I~cBct gene. 
3.2. Effect o/" l~:Bot antisense PTO on basal and IL - la - t reated 
HU VEC growth 
In order to assess the role of the I~B protein on the FGF-  
stimulated and cytokine-inhibited growth of HUVEC,  sense 
and antisense phosphothioate oligonucleotides (PTO) synthe- 
sized against the translation initiation site of the I~Bct tran- 
script were utilized to block its expression. HUVEC were 
grown in complete growth media in the presence of increasing 
concentrations of the antisense I~Bct PTO which were added 
to the medium every two days. As shown in Fig. 2A, the 
ability of the cytokine IL-lct to block the growth of HUVEC 
was not affected by the I~Bc~ antisense PTO; however, in- 
creased cell numbers were obtained in the presence of the 
l~:Bct antisense PTO and FGF-1. The ability of both sense 
and antisense I~Bct PTO to modulate the growth-inhibitory 
effect of IL-lct was investigated in detail. As shown in Fig. 2B, 
dose-dependent inhibition of HUVEC growth by IL-lc~ was 
not modulated by either sense or antisense I~Bct PTO. In 
contrast, the effect of FGF- I  to increase HUVEC cell number 
was greatly potentiated in the presence of antisense I~;Bct PTO 
but not the sense counterpart (Fig. 2C). 
The effect of cell density on the potentiation of the I~Bct 
PTO was investigated next. Different number of HUVEC 
were seeded at day 1 and the cells were grown in complete 
growth medium containing either sense or antisense bzBct 
PTO. The cell number was then determined at day 7. When 
cells were seeded at low density (5x  104 cells/well), normal 
proliferation occurred and yielded 8× 105 cells per well at 
Fig. 2. A: Effect of antisense PTO against I~cBa on basal and IL-l- 
inhibited HUVEC cell growth. HUVEC were seeded on fibronectin 
coated dishes at the density of 104 cells/well at day 1. Control cells 
received the complete growth medium (10% FBS+endothelial cell 
growth supplement in M199+heparin). Some wells were treated with 
10 ng/ml of human IL-I alpha in complete growth medium. Indi- 
cated amounts of the antisense PTO were added every two days 
and the cell number at day 10 was determined. B: Effect of I~Bc~ 
PTO on the IL-lct inhibition of HUVEC cell growth. HUVEC were 
allowed to grow as above with 10 ng/ml of FGF-1 for 10 days. 
Some cultures were treated with either sense or antisense I~cBa PTO 
in the presence of indicated concentrations of IL-lct. Cell number 
was determined at day 10. C: Effect of sense and antisense I~cBc~ 
PTO on FGF-l-induced HUVEC growth. HUVEC were seeded at 
104 cells/well at day 1 in medium 199+10% FBS+5 units/ml of hep- 
arin+indicated concentrations of purified FGF-I. Sense and anti- 
sense IKBct PTO (40 mg/ml; 6.7 mM) were added every 2 days. Cell 
number at day 10 was determined. 
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day 7. Antisense but not sense InBa PTO-treated cells how- 
ever, reached a higher saturation density of 1.25 × 106 cells per 
well. Independent of initial inoculum, the antisense I~;Bct 
PTO-treated cells achieved significantly higher saturation den- 
sity than the sense-treated or control cells. The morphology of 
antisense-treated c lls confirmed that inhibition of InBa re- 
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sulted in higher saturation density without grossly altering cell 
shape or phenotypic differentiation. 
We next determined the effect of the PTO synthesized 
against he translation i itiation site of the RelA polypeptide 
which constitutes the p65 subunit of the NF~:B protein on 
HUVEC growth. The RelA PTOs were used previously to 
show the requirement of RelA in the adhesion molecule x- 
pression of a variety of cells [32]. In addition, we have pre- 
viously shown that this PTO blocks the NF~B-dependent i -
duction of cyclooxygenase-2 in synovial fibroblasts [47]. 
Neither the sense nor antisense RelA PTO modulated FGF- 
1-induced HUVEC cell growth (data not shown). This sug- 
gests that the function of I~B independent of RelA is involved 
in the growth regulation phenomenon i  endothelial cells. 
3.3. Effect of IrBa PTO on lrdBa polypeptide xpression 
In order to confirm the effect of the antisense and sense 
I~Bc~ PTO on the synthesis of the I~cBa protein, we tested 
the ability of the PTO to influence the in vitro translation 
of the I~Bc~ mRNA in [35S]-methionine supplemented rabbit 
reticulocyte lysates. As shown in Fig. 3, addition of 1 pg of 
the I~Ba transcript directed the synthesis of the radiolabelled 
polypeptide of approximately 40kd molecular weight. Immu- 
noprecipitation f the reticulocyte lysates with the polyclonal 
I~Bct antiserum specifically precipitated the polypeptide band. 
Addition of the antisense PTO strongly inhibited (14% of 
control) the translation of the 40 kd I~B polypeptide. While 
the sense PTO also suppressed the translation somewhat (57% 
of control), the efficacy of the antisense PTO was quantita- 
tively stronger. The addition of irrelevant PTOs at similar 
concentrations also inhibited the I~Ba synthesis approxi- 
mately 40% (data not shown). This may be related to the 
non-specifc inhibition of translation i duced by high concen- 
trations of PTOs in the reticulocyte ranslation system. Never- 
theless, these data demonstrate hat the antisense I~Bct PTO is 
able to potently suppress the translation of the I~;Bct polypep- 
tide. 
We next tested the effect of the I~Bc~ PTO on the synthesis 
of basal and stimulated I~:Ba polypeptide synthesis in HU- 
VEC. Cells were treated with either sense or antisense I~;B~ 
PTO for 2 days and stimulated with 1 ng/ml of IL- la for 5 h. 
During the stimulation period, the cells were metabolically 
labelled with [35S]-methionine and -cysteine. Cell lysates 
were then immunoprecipitated with the polyclonal IKBct anti- 
serum and analyzed by polyacrylamide g l electrophoresis and 
autoradiography. As shown in Fig. 3B, the 40 kd polypeptide 
which is of similar molecular weight as the in vitro translated 
¢__ 
Fig. 3. A: Effect of bcBc~ PTO on in vitro translation f the InBc~ 
transcript. One pg of capped InBct transcript was translated in the 
rabbit reticulocyte lysates supplemented with [zss]-methionine either 
in the presence or absence of 1 ~tg of PTO. Samples were separated 
on 12% SDS-PAGE and autoradiographed. Data indicate a repre- 
sentative experiment which was repeated twice. B: Effect of boB 
PTO on de novo synthesis of InBct protein. HUVEC were treated 
with PTO for 2 days and stimulated with IL-I~ for 4 h during 
which time the cells were metabolically abelled with [35S]-methio- 
nine/cysteine mixture. Cell lysates were immunoprecipitated with a 
polyclonal antibody raised against the recombinant human lnB~ 
protein, separated on a 12%,, SDS-PAGE and autoradiographed. 
Note that the IL-hx induction of IKBc~ is selectively blocked by the 
antisense PTO. The densitometric scan of this autoradiograph is 
shown in (C). 
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I~cBc~ protein was immunoprecipitated. The radiolabelling of 
the 40 kd band was induced approximately 3-fold by IL-I 
treatment in control and sense bcBc~ PTO-treated cells but 
not in the antisense DcBa PTO-treated cells. This further pro- 
vides evidence that the antisense I~;BR PTO is able to repress 
the expression of the IKB polypeptide in HUVEC. 
4. Discussion 
Using differential hybridization [26] as well as the PCR- 
ASH techniques [23], we have isolated from HUVEC, several 
PMA-inducible IE genes such as an orphan G-protein- 
coupled receptor edg-1 [26], collagenase type I [23] and cyclo- 
oxygenase-2 [33]. In this communication, we describe the 
characterization of edg-3 which is identical to the I~cBo~ gene 
product. The edg-3 cDNA is strongly and transiently induced 
by PMA in HUVEC. Recent studies on the regulation of the 
InBc~ gene indicate that the tandem repeats of the cis-acting 
NFnB enhancer elements control the transcription of the 
I~:B~ gene itself [35]. Thus, the transcription of the inhibitor 
is under tight regulation by the transcription factor itself, 
constituting a mutual autoregulatory loop [36]. Because of 
the extreme lability of the l~:Bc~ protein [37] and the transcrip- 
tional autoregulatory loop, the I~;Bct protein is being recog- 
nized as a major conduit of extracellular signals in inflamma- 
tory gene transcription [29,36,46]. 
In addition to its well-established role as a regulator of 
transcription of inducible genes, the Rel family of proteins 
also regulate cell growth, oncogenesis and apoptosis [38]. In 
that respect, the [tcBa polypeptide can i teract with multiple 
members of the Rel family, including the c-Rel, ReI-A and 
ReI-B polypeptides [39,40]. It was recently shown that the 
protooncogene c-Rel is found associated with I~:Bc~ in the 
cytoplasm and in contrast o the ReI-A/InBa complex, inflam- 
matory cytokine treatment did not result in the nuclear trans- 
location of the c-Rel polypeptide in HUVEC [41]. This indi- 
cated that there may be additional I~¢Ba-mediated signalling 
pathways distinct from the well-known transcriptional regula- 
tory function of NF~cB. Indeed, ankyrin repeat-containing 
polypeptides that are structurally related to DcB are known 
regulators of mating-type switching in S, cerevesiae (SW[4 
and SWI6) [42] and leukemogenesis in humans (bcl3) [43], 
While the c-Rel polypeptide was originally characterized as 
a protooncogene involved in growth regulation [44], recent 
studies have indicated that c-Rel may also regulate the process 
of apoptosis during development [45]. It is generally thought 
that different combinatorial Rel complexes are involved in the 
mediation of diverse nuclear signalling events; however, spe- 
cific biological role of distinct Rel complexes are not well 
understood. In addition, cytoplasmic regulation (retention) 
of distinct complexes by the I~cB family members and the 
corresponding signalling pathways are not well defined. 
Our data indicate that the antisense I~:Bc~ PTO specifically 
enhances the fibroblast growth factor-dependent cell growth 
of HUVEC. In contrast, the antisense IKzBc~ PTO does not 
modulate the IL-l- induced growth arrest in HUVEC. The 
sense IKBc~ PTO, however, did not have appreciable ffects 
on protein synthesis or HUVEC growth. Because the anti- 
sense hcBc~ PTO inhibited the in vitro translation of the 
IKBc~ transcript and suppressed the de novo synthesis of the 
polypeptide in IL-lc~-treated HUVEC, perturbation of the 
normal turnover of the hcBc~ protein results in the enhanced 
endothelial cell density upon reaching confluence. 
Data presented in this report suggest hat the InBc~ protein 
is involved in a signalling pathway that limits the growth of 
HUVEC. The increase in saturation density of HUVEC can 
result from either increased cell growth due to the loss of 
contact inhibition or decreased cell death due to apoptosis. 
Alternatively, both of these mechanisms may be operative. 
Further understanding of the DcBc~-mediated growth regula- 
tory pathway in vascular endothelial ce ls may yield insights 
into mechanisms of angiogenesis. 
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